Recent developments in natural product-based drug discovery for tuberculosis

Maryline Dong; Bernhard Pfeiffer; Karl-Heinz Altmann

doi:10.1016/j.drudis.2016.11.015

Recent developments in natural product-based drug discovery for tuberculosis

Drug Discov Today. 2017 Mar;22(3):585-591. doi: 10.1016/j.drudis.2016.11.015. Epub 2016 Nov 24.

Authors

Maryline Dong¹, Bernhard Pfeiffer¹, Karl-Heinz Altmann²

Affiliations

¹ ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, HCI H 405, CH-8093 Zürich, Switzerland.
² ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, HCI H 405, CH-8093 Zürich, Switzerland. Electronic address: karl-heinz.altmann@pharma.ethz.ch.

PMID: 27890820
DOI: 10.1016/j.drudis.2016.11.015

Abstract

Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB). Although the current clinical TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb). This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb. These compounds could help to replenish the dry clinical TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antitubercular Agents* / pharmacology
Antitubercular Agents* / therapeutic use
Biological Products* / pharmacology
Biological Products* / therapeutic use
Drug Discovery
Humans
Peptides / pharmacology
Peptides / therapeutic use
Tuberculosis / drug therapy

Substances

Antitubercular Agents
Biological Products
Peptides